Tumors of central and peripheral nervous system associated with inherited genetic syndromes

Pediatric Neurosurgery

Volumn 48, Issue 5, 2013, Pages 271-285

  Stefanaki, Kalliopi ^a   Alexiou, George A ^b   Stefanaki, Christina ^a   Prodromou, Neofytos ^b  

^a AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^b Agia Sofia Childrens' Hospital   (Greece)

Author keywords

Central nervous system; Genetic syndromes; Peripheral nervoussystem; Tumor

Indexed keywords

ALPHA CRYSTALLIN; BETA CRYSTALLIN; CARCINOEMBRYONIC ANTIGEN; COLLAGEN FIBER; CYTOKERATIN; EVEROLIMUS; GLIAL FIBRILLARY ACIDIC PROTEIN; HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN; MERLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53; PROTEIN S 100; RAF PROTEIN; RAPAMYCIN; RETICULIN; RIDAFOROLIMUS; SYNAPTOPHYSIN; TEMSIROLIMUS; TUBERIN; VIMENTIN; BLOOD CLOTTING FACTOR 8; CD31 ANTIGEN; CD34 ANTIGEN; CD57 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN 8; INHIBIN; MYELIN BASIC PROTEIN; NERVE CELL ADHESION MOLECULE; NESTIN; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; PROTEIN P27; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

BASAL CELL NEVUS SYNDROME; CENTRAL NERVOUS SYSTEM TUMOR; CHROMOSOME 16P; CHROMOSOME 9Q; COWDEN SYNDROME; DISEASE ASSOCIATION; FAMILIAL CANCER; FRAMESHIFT MUTATION; GENETIC DISORDER; GENOTYPE PHENOTYPE CORRELATION; GLIOMA; HEMANGIOBLASTOMA; HETEROZYGOSITY LOSS; IMMUNOHISTOCHEMISTRY; LHERMITTE DUCLOS DISEASE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MENINGIOMA; MOLECULAR GENETICS; NERVOUS SYSTEM TUMOR; NEURILEMOMA; NEUROFIBROMA; NEUROFIBROMATOSIS; PERIPHERAL NERVOUS SYSTEM TUMOR; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RHABDOID PREDISPOSITION SYNDROME; SCHWANNOMATOSIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TUBEROUS SCLEROSIS; TURCOT SYNDROME; VON HIPPEL LINDAU DISEASE; WESTERN BLOTTING; ASTROCYTOMA; FIBROBLAST; GANGLIONEUROMA; GASTROINTESTINAL STROMAL TUMOR; GENE LOCUS; GENETIC PREDISPOSITION; GERMLINE MUTATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; PERIPHERAL NERVE TUMOR; RHABDOID TUMOR; SCHWANN CELL; SPINDLE CELL;

ANIMALS; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COLORECTAL NEOPLASMS; HUMANS; LI-FRAUMENI SYNDROME; NEOPLASTIC SYNDROMES, HEREDITARY; NEUROFIBROMATOSIS 1; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; SYNDROME; TUBEROUS SCLEROSIS; VON HIPPEL-LINDAU DISEASE;

EID: 84883187393     PISSN: 10162291     EISSN: 14230305     Source Type: Journal    
DOI: 10.1159/000351546     Document Type: Review

References (70)

1. Familial tumour syndromes involving the nervous system; in Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): World Health Organization Classification of Tumours of the Central Nervous System. Lyon, IARC Press, 2007, pp 205-235.
2. Burger PC, Scheithauer B: Dysgenetic diseases; in Burger PC, Scheithauer B (eds): Tumors of the Central Nervous System. AFIP Atlas of Tumor Pathology. Washington, AFIP, 2007, series 4, pp 503-518.
3. Deimling A, Perry A: Neurofibromatosis type 1; in Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): World Health Organization Classification of Tumours of the Central Nervous System. Lyon, IARC Press, 2007, pp 205-209.
4. Hottinger AF, Khakoo Y: Neuro-oncology of neurofibromatosis type 1. Curr Treat Options Neurol 2009; 11: 306-314.
5. Brems H, Beert E, de Ravel T, Legius E: Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 2009; 10: 508-515.
6. Rodriguez FJ, Folpe AL, Giannini C, Perry A: Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol 2012; 123: 295-319.
7. Widemann BC: Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep 2009; 11: 322-328.
8. Ingham S, Huson SM, Moran A, Wylie J, Leahy M, Evans DG: Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years. Eur J Cancer 2011; 47: 2723-2728.
9. Upadhyaya M: Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors. Front Biosci 2011; 16: 937-951.
10. Yu J, Deshmukh H, Payton JE, Dunham C, Scheithauer BW, Tihan T, Prayson RA, Guha A, Bridge JA, Ferner RE, Lindberg GM, Gutmann RJ, Emnett RJ, Salavaggione L, Gutmann DH, Nagarajan R, Watson MA, Perry A: Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res 2011; 17: 1924-1934.
11. Rodriguez FJ, Perry A, Gutmann DH, et al: Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. Neuropathol Exp Neurol 2008; 67: 240-249.
12. Patil S, Chamberlain RS: Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist 2012; 17: 101-116.
13. Rosser T, Packer RJ: Intracranial neoplasms in children with neurofibromatosis 1. J Child Neurol 2002; 17: 630-636.
14. Lind-Landström T, Habberstad AH, Sundstrøm S, Torp SH: Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol 2012; 5: 152-158.
15. Scheffzek K, Ahmadian MR, Wiesmüller L, Kabsch W, Stege P, Schmitz F, Wittinghofer A: Structural analysis of the GAP-related domain from neurofibromin and its implications. EMBO J 1998; 17: 4313-4327.
16. Larizza L, Gervasini C, Natacci F, Riva P: Developmental abnormalities and cancer predisposition in neurofibromatosis type 1. Curr Mol Med 2009; 9: 634-653.
17. Pasmant E, Sabbagh A, Spurlock G, et al: NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat 2010; 31:E1506-E1518.
18. Laycock-van Spyk S, Thomas N, Cooper DN, Upadhyaya M: Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genom 2011; 5: 623-690.
19. Brekke HR, Ribeiro FR, Kolberg M, Agesen TH, Lind GE, Eknaes M, Hall KS, Bjerkehagen B, van den Berg E, Teixeira MR, Mandahl N, Smeland S, Mertens F, Skotheim RI, Lothe RA: Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J Clin Oncol 2010; 28: 1573-1582.
20. Evans DG, Sainio M, Baser ME: Neurofibromatosis type 2. J Med Genet 2000; 37: 897-904.
21. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR: Neurofibromatosis type 2. Lancet 2009; 373: 1974-1986.
22. Stemmer-Rachamimov AQ, Wiestler OD, Louis DN: Neurofibromatosis type 2; in Louis DN, Ohgaki H, Wiestler O.D, Cavenee WK (eds): World Health Organization Classification of Tumours of the Central Nervous System. Lyon, IARC Press, 2007, pp 210-214.
23. Evans GR, Lloyd SK, Ramsden RT: Neurofibromatosis type 2. Adv Otorhinolaryngol 2011; 70: 91-98.
24. Scheithauer BW, Louis DN, Hunter S, Woodruff JM, Antonescu CR: Schwannoma; in Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): World Health Organization Classification of Tumours of the Central Nervous System. Lyon, IARC Press, 2007, pp 152-155.
25. Geddes JF, Sutcliffe JC, King TT: Mixed cranial nerve tumors in neurofibromatosis type 2. Clin Neuropathol 1995; 14: 310-313.
26. Rodriguez FJ, Stratakis CA, Evans DG: Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes. Acta Neuropathol 2012; 123: 349-367.
27. Casadei GP, Komori T, Scheithauer BW, Miller GM, Parisi JE, Kelly PJ: Intracranial parenchymal schwannoma. A clinicopathological and neuroimaging study of nine cases. J Neurosurg 1993; 79: 217-222.
28. Goutagny S, Bah AB, Henin D, Parfait B, Grayeli AB, Sterkers O, Kalamarides M: Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neurooncology 2012; 14: 1090-1096.
29. Wiestler OD, von Siebenthal K, Schmitt HP, Feiden W, Kleihues P: Distribution and immunoreactivity of cerebral micro-hamartomas in bilateral acoustic neurofibromatosis (neurofibromatosis 2). Acta Neuropathol 1989; 79: 137-143.
30. Morrow KA, Shevde LA: Merlin: the wizard requires protein stability to function as a tumor suppressor. Biochim Biophys Acta 2012; 1826: 400-406.
31. James MF, Han S, Polizzano C, et al: NF2/merlin is a novel negative regulator of mTOR complex 1 and activation of mTORC1 is associated with meningioma and schwannoma growth. Moll Cell Biol 2009; 29: 4250-4261.
32. Perry A, Louis DN, Scheithauer B, Budka H, von Deimling A: Meningioma; in Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): World Health Organization Classification of Tumours of the Central Nervous System. Lyon, IARC Press, 2007, pp 164-172.
33. Alexiou GA, Markoula S, Gogou P, Kyritsis AP: Genetic and molecular alterations in meningiomas. Clin Neurol Neurosurg 2011; 113: 261-267.
34. Uhlmann EJ, Plotkin SR: Neurofibromatoses. Adv Exp Med Biol 2012; 724: 266-277.
35. Jacoby LB, Jones D, Davis K, Kronn D, Short MP, Gusella J: Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet 1997; 61: 1293-1302.
36. Patil S, Perry A, Maccollin H, et al: Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas but not in solitary sporadic schwannomas. Brain Pathol 2008; 18: 517-519.
37. Swensen JJ, Kayser J, Coffin CM, et al: Familial occurrence of schwannoma and malignant rhabdoid tumour associated with duplication in SMARCB1. J Med Genet 2009; 46: 68-72.
38. Lopes MBS, Wiestler OD, Stemmer-Rachamimov AO, Sharma MC: Tuberous sclerosis complex and subependymal giant cell astrocytoma; in Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): World Health Organization Classification of Tumours of the Central Nervous System. Lyon, IARC Press, 2007, pp 218-221.
39. Roach ES, Sparagana SP: Diagnosis of tuberous sclerosis complex. J Child Neurol 2004; 19: 643-649.
40. Buccofilero AM, Franchi A, Castiglione F, et al: Subependymal giant cell astrocytoma (SEGA): is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology 2009; 29: 25-30.
41. Napolioni V, Curatolo P: Genetics and molecular biology of tuberous sclerosis complex. Curr Genom 2008; 9: 475-487.
42. Jozwiak J, Jozwiak S, Wlodarski P: Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol 2008; 9: 73-79.
43. Sampson JR: Therapeutic targeting of mTOR in tuberous sclerosis. Biochem Soc Trans 2009; 37: 259-264.
44. Franz DN, Weiss BD: Molecular therapies for tuberous sclerosis and neurofibromatosis. Curr Neurol Neurosci Rep 2012; 12: 294-301.
45. Beaumont TL, Limbrick DD, Smyth MD: Advances in the management of subependymal giant cell astrocytoma. Childs Nerv Syst 2012; 28: 963-968.
46. Eberhart CG, Wiestler OD, Eng C: Cowden disease dysplastic gangliocytoma of the cerebellum/Lhermitte-Duclos disease; in Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): World Health Organization Classification of Tumours of the Central Nervous System. Lyon, IARC Press, 2007, pp 226-228.
47. Pilarski R: Cowden syndrome: a critical review of the clinical literature. J Genet Couns 2009; 18; 13-27.
48. Nair P, Pal L, Jaiswal AK, Behari S: Lhermitte-Duclos disease associated with dysembryoplastic neuroepithelial tumor differentiation with characteristic magnetic resonance appearance of 'tiger striping'. World Neurosurg 2011; 75: 699-703.
49. Kumar R, Vaid VK, Kalra SK: Lhermitte-Duclos disease. Childs Nerv Syst 2007; 23: 729-732.
50. Alexiou GA, Voulgaris S: The role of the PTEN gene in malignant gliomas. Neurol Neurochir Pol 2010; 44: 80-86.
51. Plate KH, Vortmeyer AO, Zagzag D, Neuman HPH: Von Hippel-Lindau disease and hemangioblastoma; in Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): World Health Organization Classification of Tumours of the Central Nervous System. Lyon, IARC Press, 2007, pp 215-218.
52. Maher ER, Neumann HP, Richard S: Von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet 2011; 19: 617-623.
53. Ammerman JM, Lonser RR, Dambrosia J, Butman JA, Oldfield EH: Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg 2006; 105: 248-255.
54. Aldape KD, Plate KH, Vortmeyer AO, Zagzag D, Neumann HPH: Hemangioblastoma; in Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): World Health Organization Classification of Tumours of the Central Nervous System. Lyon, IARC Press, 2007, pp 184-186.
55. Alexiou GA, Tsiouris S, Voulgaris S, Doukas M, Goussia A, Kyritsis AP, Polyzoidis KS, Fotopoulos AD: Brain scintigraphy with 99 mTctetrofosmin for the differential diagnosis of a posterior fossa tumor. Hell J Nucl Med 2008; 11: 114-117.
56. Bader HL, Hsu T: Systemic VHL gene functions and the VHL disease. FEBS Lett 2012; 586: 1562-1569.
57. Reuss D, von Deimling A: Hereditary tumor syndromes and gliomas. Recent Results Cancer Res 2009; 171: 83-102.
58. Cavenee WK, Burger PC, Leunig SY, van Meier EG: Turcot syndrome; in Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): World Health Organization Classification of Tumours of the Central Nervous System. Lyon, IARC Press, 2007, pp 229-231.
59. Skomorowski M, Taxier M, Wise W Jr: Turcot syndrome type 2: medulloblastoma with multiple colorectal adenomas. Clin Gastroenterol Hepatol 2012; 10:A24.
60. De Bont JM, Packer RJ, Michiels EM, den Boer ML, Pieters R: Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neurooncology 2008; 10: 1040-1060.
61. Royds JA, Iacopetta B: p53 and disease: when the guardian angel fails. Cell Death Differ 2006; 13: 1017-1026.
62. Oghaki H, Oliver M, Hainaut P: Li-Fraumeni syndrome and TP53 germline mutations; in Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): World Health Organization Classification of Tumours of the Central Nervous System. Lyon, IARC Press, 2007, pp 222-225.
63. Eberhart CG, Cavenee WK, Pietsch T: Naevoid basal cell carcinoma syndrome; in Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): World Health Organization Classification of Tumours of the Central Nervous System. Lyon, IARC Press, 2007, pp 232-233.
64. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F: Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010; 152: 327-332.
65. Evans DG, Ladusans EJ, Rimmer S, Burnell LD, Thakker N, Farndon PA: Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet 1993; 30: 460-464.
66. Cowan R, Hoban P, Kelsey A, Birch JM, Gattamaneni R, Evans DG: The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. Br J Cancer 1997; 76: 141-145.
67. Amlashi SF, Riffaud L, Brassier G, Morandi X: Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. Cancer 2003; 98: 618-624.
68. Pathi S, Pagan-Westphal S, Baker DP, Garber EA, Rayhorn P, Bumcrot D, Tabin CJ, Blake Pepinsky R, Williams KP: Comparative biological responses to human Sonic, Indian, and Desert hedgehog. Mech Dev 2001; 106: 107-117.
69. Yoon JW, Gilbertson R, Iannaccome S, et al: Defining a role for sonic hedgehog pathway activation in desmoplastic medulloblastoma by identifying GLI1 target genes. Int J Cancer 2009; 124: 109-119.
70. Wesseling P, Biegel JA, Eberhart CG, Judkins AR: Rhabdoid predisposition syndrome; in Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): World Health Organization Classification of Tumours.of the Central Nervous System. Lyon, IARC Press, 2007, pp 234-235.